Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency

Journal of Cardiology

Volumn 54, Issue 2, 2009, Pages 192-198

  Yoshida, Susumu ^a   Kamihata, Hiroshi ^a   Nakamura, Seishi ^b   Senoo, Takeshi ^a   Manabe, Kenichi ^a   Motohiro, Masayuki ^a   Sugiura, Tetsuro ^c   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Takarazuka Municipal Hospital   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Contrast volume; Contrast induced nephropathy; Pravastatin; Pre procedure serum creatinine

Indexed keywords

CONTRAST MEDIUM; CREATININE; PRAVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYDRATION; HYPERCHOLESTEROLEMIA; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT;

AGED; ANGIOPLASTY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PRAVASTATIN; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 70349244784     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.05.006     Document Type: Article

References (26)

1. Parfrey P., Griffiths S., and Barrett B. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency or both: a prospective controlled study. N Engl J Med 320 (1989) 143-149
2. Rihal C.S., Textor S.C., Grill D.E., Berger P.B., Ting H.H., Best P.J., Singh M., Bell M.R., Barsness G.W., Mathew V., Garratt K.N., and Holmes Jr. D.R. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 (2002) 2259-2264
3. Dangas G., Iakovou I., Nikolsky E., Aymong E.D., Mintz G.S., Kipshidze N.N., Lansky A.J., Moussa I., Stone G.W., Moses J.W., Leon M.B., and Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95 (2005) 13-19
4. Russo D., Minutolo R., Cianciaruso B., Memoli B., Conte G., and De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 6 (1995) 1451-1458
5. Bagshaw S.M., and Ghali W.A. Theophylline for prevention of contrast-induced nephropathy. Arch Intern Med 165 (2005) 1087-1093
6. Meschi M., Detrenis S., Musini S., Strada E., and Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 34 (2006) 2060-2068
7. Crisby M., Nordin-Fredriksson G., Prediman K.S., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteases, and cell death in human carotid plaques. Circulation 103 (2001) 926-933
8. Bellosta S., Ferri N., Bernini F., Paoletti R., and Corsini A. Non-lipid-related effects of statins. Ann Intern Med 103 (2000) 926-933
9. Teshima Y., Yufu K., Akioka H., Iwao T., Anan F., Nakagawa M., Yonemochi H., Takahashi N., Hara M., and Saikawa T. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol 53 (2009) 58-64
10. Kadota S., Matsuda M., Izuhara M., Baba O., Moriwak S., Shioji K., Takeuchi Y., and Uegaito T. Long-term effects of early statin therapy for patients with acute myocardial infarction treated with stent implantation. J Cardiol 51 (2008) 171-178
11. Khanal S., Attallah N., Smith D.E., Kline-Rogers E., Share D., O'Donnell M.J., and Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118 (2005) 843-849
12. Tonelli M., Isles C., Craven T., Tonkin A., Pfeffer M.A., Shepherd J., Sacks F.M., Furberg C., Cobbe S.M., Simes J., West M., Packard C., and Curhan G.C. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
13. Schwab S.J., Hlatky M.A., Pieper K.S., Davidson C.J., Morris K.G., Skelton T.N., and Bashore T.M. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 320 (1989) 149-153
14. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-34
15. Morcos S.K. Prevention of contrast media nephrotoxicity: the story so far. Clin Radiol 59 (2004) 381-389
16. Gruberg L., Mintz G.S., Mehran R., Gangas G., Lansky A.J., Kent K.M., Pichard A.D., Satler L.F., and Leon M.B. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36 (2000) 1542-1548
17. Mach F. Statins as immunomodulatory agents. Circulation 109 21 Suppl. 1 (2004) II15-II17
18. Schonbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statin as anti-inflammatory agents?. Circulation 109 21 Suppl. 1 (2004) II18-II26
19. Puccetti L., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., Angori P., Auteri A., and Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolemia. Eur J Clin Invest 32 (2002) 901-908
20. Mason R.P., Water M.F., and Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109 21 Suppl. 1 (2004) II34-II41
21. Lee T.M., Su S.F., and Tsai C.H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40 (2002) 67-73
22. Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., and Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet 368 (2006) 1155-1163
23. Yada T., Nakata M., Shiraishi T., and Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+signaling and insulin secretion due to blockade of L type Ca2+channels in rat islet beta-cells. Br J Pharmacol 126 (1999) 1205-1213
24. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., and Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4): implications in glycaemic contral. Diabetologia 49 (2006) 1881-1892
25. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trial. J Am Coll Cardiol 50 (2007) 409-418
26. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., and Weiss M.F. Glycation of mitochondrial proteins from diabetic rat kidney is associates with excess superoxide formation. Am J Physiol Renal Physiol 289 (2005) F420-F430